Lead Product(s) : Sulforaphane
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evgen Pharma Recruits First Patient in STAR Trial
Details : This Phase II/III trial will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for s...
Product Name : SFX-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Sulforaphane
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable